Co-fluampicil: Difference between revisions
m Protected "Co-fluampicil": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 21: | Line 21: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Co-fluampicil''' is the [[British Approved Name]], for the combination of [[ampicillin]] and [[flucloxacillin]] β-lactam [[antibiotic]]s (trade name '''Magnapen'''). | '''Co-fluampicil''' is the [[British Approved Name]], for the combination of [[ampicillin]] and [[flucloxacillin]] β-lactam [[antibiotic]]s (trade name '''Magnapen'''). | ||
Line 43: | Line 43: | ||
[[Category:combination antibiotics]] | [[Category:combination antibiotics]] | ||
[[Category:Beta-lactam antibiotics]] | [[Category:Beta-lactam antibiotics]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WS}} | {{WS}} |
Latest revision as of 23:59, 8 August 2012
Combination of | |
---|---|
Ampicillin | Moderate-spectrum penicillin |
Flucloxacillin | Antistaphylococcal penicillin |
[[{{{component3}}}]] | ? Class |
[[{{{component4}}}]] | ? Class |
[[{{{component5}}}]] | ? Class |
Clinical data | |
Routes of administration | Oral, intravenous |
ATC code | |
Identifiers | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
WikiDoc Resources for Co-fluampicil |
Articles |
---|
Most recent articles on Co-fluampicil Most cited articles on Co-fluampicil |
Media |
Powerpoint slides on Co-fluampicil |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Co-fluampicil at Clinical Trials.gov Trial results on Co-fluampicil Clinical Trials on Co-fluampicil at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Co-fluampicil NICE Guidance on Co-fluampicil
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Co-fluampicil Discussion groups on Co-fluampicil Patient Handouts on Co-fluampicil Directions to Hospitals Treating Co-fluampicil Risk calculators and risk factors for Co-fluampicil
|
Healthcare Provider Resources |
Causes & Risk Factors for Co-fluampicil |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Co-fluampicil is the British Approved Name, for the combination of ampicillin and flucloxacillin β-lactam antibiotics (trade name Magnapen).
Indication
Ampicillin is a moderate spectrum penicillin antibiotic with good cover against Group A streptococcal infection whilst Flucloxacillin is a narrow spectrum antibiotic with cover against Staphylococcus aureus. The combination covers the two most likely bacteria in cellulitis infections in the arm or leg.
Formulations
As Co-fluampicil 250/250 capsules containing 250mg of each component, Co-fluampicil 125/125 syrup or as Co-fluampicil 250/250 powder for reconstruction for intravenous injection.
Dosage
Typical oral dosage is Co-fluampicil 250/250 four times a day, doubled in severe infection and half the dose for children under 10 years.
Side-effects
As per the individual components with stomach or bowel upset from the Flucloxacillin being the most common. Both parts are members of the penicillin family of antibiotics, and therefore should not be taken by patients allergic to penicillin. See Flucloxacillin for additional contraindications.
References
- British National Formulary '50' September 2005
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Combination antibiotics
- Beta-lactam antibiotics